Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Diabet Med. 2019 Feb 28;36(9):1149–1157. doi: 10.1111/dme.13878

Table 1.

Baseline characteristics of the study sample (N=8895)

Depressed (n=1443) Non-depressed (n =7452) P*
  n   %   n   %

Race/ethnicity <0.0001
 Non-Hispanic white 887 61.5 5058 67.9
 Hispanic 153 10.6 371 5.0
 Black 317 22.0 1525 20.5
 Other 82 5.7 477 6.4
 Unknown 4 0.3 21 0.3
Education <0.0001
 ≤High school 540 37.4 2240 30.1
 Some college/ vocational 590 40.9 3038 40.8
 4-year college degree 98 6.8 575 7.7
 Postgraduate 197 13.7 1549 20.8
 Unknown 18 1.2 50 0.7
Income <0.0001
 < $50,000 1107 76.7 5221 70.1
 $50,000–$99,999 190 13.2 1486 19.9
 ≥ $100,000 25 1.7 268 3.6
 Unknown 121 8.4 477 6.4
Marital status <0.0001
 Married/ partnered 661 45.8 4136 55.5
 Not married/ partnered 766 53.1 3275 43.9
 Unknown 16 1.1 41 0.5
Number of comorbid conditions <0.0001
 0 132 9.1 930 12.5
 1 350 24.3 2262 30.4
 ≥2 959 66.5 4246 57.0
 Unknown 2 0.1 14 0.2
Antidepressant medication use <0.0001
 None 1144 79.3 6815 91.5
 Tetracyclics 0 0.0 0 0.0
 MAO inhibitors 0 0.0 1 0.0
 Modified cyclics 32 2.2 48 0.6
 SSRIs 170 11.8 223 3.0
 Tricyclic agents 87 6.0 341 4.6
 Miscellaneous 10 0.7 24 0.3

 Mean (SD)  Range n  Mean (SD)  Range n
Age at baseline 62.9 (7.1) 50–79 1443 64.7 (6.8) 50–79 7452 <0.0001
Social support 29.6 (9.0) 9–45 1391 35.2 (8.1) 9–45 7240 <0.0001
Optimism 20.0 (3.9) 6–30 1379 22.9 (3.3) 9–30 7236 <0.0001

MAO, monoamine oxidase; SSRI, selective serotonin reuptake inhibitor.

*

P values are for comparisons across depressive symptom groups based on independent samples t-test for continuous variables and chi-squared test for categorical variables.